Results 161 to 170 of about 349,588 (308)

Delayed Recognition of Thrombotic Thrombocytopenic Purpura Following Platelet Transfusion: A Clinical Pitfall. [PDF]

Clin Case Rep
Al-Dawoudi A, Dalain M, Varlamov D, Alhallak S, Freimanis D.   +4 more
europepmc   +1 more source

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

British Journal of Haematology, EarlyView.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo, Maria Georgiou, Donal P. McLornan, Claire N. Harrison   +3 more
wiley   +1 more source

ICU Clinicians' View on Platelet Transfusion Thresholds for a Future Trial-Protocol for an International Survey. [PDF]

Acta Anaesthesiol Scand
Barakji JA, Anthon CT, Granholm A, Møller MH, Stensballe J, Perner A.   +5 more
europepmc   +1 more source

From haemostasis to immunity: The expanding frontiers of platelet biology

British Journal of Haematology, EarlyView.
Platelets are versatile cells whose functions extend far beyond haemostasis and thrombosis, actively regulating innate and adaptive immunity, angiogenesis, lymphangiogenesis, liver regeneration, atherosclerosis and tumour metastasis. This demonstrates their central role in various physiological processes and multiple life‐threatening diseases ...
Xun Grace Wu, Nicole Tomei, Heyu Ni
wiley   +1 more source

Platelet Transfusion:2025 AABB and ICTMG International Clinical Practice Guidelines

Importance: Platelet transfusion is a frequent procedure with benefits and risks. Objective: To provide recommendations in adult and pediatric populations in whom platelet transfusions are commonly performed.
Kranke, Peter, Fung, Mark K., Metcalf, Ryan A., Bathla, Aarti, Murphy, Michael F., Møller, Morten H., DeAnda, Abe, Saifee, Nabiha H., Waters, Jonathan, Hess, Aaron S., Jug, Rachel C., Kaufman, Richard M., Hume, Heather A., Uberoi, Raman, Szczepiorkowski, Zbigniew M., Callum, Jeannie L., Al-Riyami, Arwa Z., Pagano, Monica B., Patidar, Gopal K., Louw, Vernon J., Zeller, Michelle P., Guyatt, Gordon, Muszynski, Jennifer A., Stolla, Moritz, Pavenski, Katerina, Desimone, Robert A., Nahirniak, Susan, Estcourt, Lise J., O'kelly, Cian J., Poston, Jacqueline N., Cohn, Claudia S., Goel, Ruchika, La Rocca, Ursula, Williams, Brittney, White, Sandra K., Wood, Erica M., Stanworth, Simon J., Zantek, Nicole D., Filipescu, Daniela C., Grossman, Brenda J., Tobian, Aaron A. R., Dubon, Allan   +41 more
core   +1 more source

Consideration in Platelet Transfusion-Transmitted Klebsiella pneumoniae Sepsis: A Case Report. [PDF]

Cureus
V D Rezende A, Dahmen Rodrigues L, Del Pilar Bayona Molano M, Dagal A, Macruz T.   +4 more
europepmc   +1 more source

Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era

British Journal of Haematology, EarlyView.
Summary Data on real‐world survival and treatment patterns in large, unselected myelofibrosis (MF) cohorts remain limited. We analysed 1649 patients with MF diagnosed from 2010 onwards and included in the Spanish Myelofibrosis Registry across 64 centres. Janus kinase (JAK) inhibitors were administered to approximately half of the patients.
Juan‐Carlos Hernández‐Boluda, Eduardo Arellano‐Rodrigo, Manuel Pérez‐Encinas, José‐María Raya, María‐Teresa Gómez‐Casares, Francisca Ferrer‐Marín, Alberto Hernández‐Sánchez, María‐Laura Fox, Anna Angona, Beatriz Cuevas, María‐Isabel Mata‐Vázquez, Rosa Ayala, Natalia de las Heras, Elvira Mora, Valentín García‐Gutiérrez, Alicia Senín, Jasson Villarreal, Blanca Xicoy, Raúl Pérez‐López, María García‐Fortes, Sonia González de Villambrosia, Elena Magro, María‐José Ramírez, Paula Gómez, Angel Ramírez‐Payer, Clara Martínez‐Valverde, Lucía Pérez‐Lamas, Carmen García‐Hernández, Mercedes Gasior, Luis‐Miguel Juárez‐Salcedo, Francisco Ibáñez, María‐Luisa Antelo, Lucía Guerrero, Alberto Alvarez‐Larrán, Arturo Pereira, on behalf of the Spanish MPN Group (GEMFIN)   +35 more
wiley   +1 more source

Recombinant Human Thrombopoietin Reduces the Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia. [PDF]

Am J Hematol
Han Y, Lin N, Xu J, Wang S, Jin J, Shang J, Xin Y, Tan Y, Zhang D, Hou J, An P, Xie W, Guan Y, Xiong Q, Wu H, Ding H, Chen Y, Li R, Wen Z, Lu M, Yang J, Zhou Z, Zhou Y, Yu Z, Lin K, Wang W, Huang Y, Nan Y, Luo X, Shi R, Kang Y, Han T, Chen S, Wang K, Shan Y, Li J, Liu P, Lu Z, Chen J, Liu Z, Zhang L, Yang L, Sheng J, Zeng Z, Yu Y, Xu X.   +45 more
europepmc   +1 more source

Associations of blood donor and product characteristics with platelet transfusion outcomes. [PDF]

Blood Adv
Roubinian NH, Plimier C, Thomas KA, Spencer BR, Bravo M, Goel R, Baumann Kreuziger L, Hod EA, Custer B, Kleinman S, Norris PJ, Busch MP.   +11 more
europepmc   +1 more source

Janus kinase inhibitors after ruxolitinib failure in myelofibrosis: A systematic review and pooled analysis of phase 3 efficacy and integrated safety across clinical trials and real‐world evidence

British Journal of Haematology, EarlyView.
Summary Ruxolitinib remains first‐line standard of care for symptomatic myelofibrosis, but resistance/intolerance develops in most patients. Three Janus kinase inhibitors (JAKis) have entered the post‐ruxolitinib space via distinct pivotal trials. We systematically searched prospective trials evaluating JAKi in refractory adults with myelofibrosis ...
Andrea Duminuco, Patrick Harrington, Elena Torre, Hillary Catellani, Novella Pugliese, Matteo Pacilli, Annalisa Santisi, Arianna Sbriglione, Giuseppe A. Palumbo   +8 more
wiley   +1 more source